|
FOR
IMMEDIATE RELEASE
April
22, 2005.
GSK
extends agreement with Peakdale for discovery research.
Chapel-en-le-Frith,
UK, 22nd April 2005 – Peakdale Molecular announces the extension
of its agreement with GlaxoSmithKline (GSK) to provide ongoing services
for the Respiratory and Inflammation Centre of Excellence for Drug
Discovery (RI CEDD).
Under the extension of the agreement through 2005, GSK continues
to make use of Peakdale's synthetic chemistry abilities, and have
expanded the agreement to include support for GSK’s Cardiovascular
and Urogenital (CVU) CEDD.
Kim Morrison, Peakdale CEO, commented, “Peakdale is known for its
abilities to devise new synthetic routes to challenging compounds
in a flexible and responsive service, delivering on time and in
full. This revised agreement gives GSK continuation of a dedicated
team of chemists for the duration of the projects.”
About
Peakdale Molecular
Peakdale Molecular was founded in 1992. Today, the Company’s customers
include global pharmaceutical majors and an increasing number of
biotechnology companies. Its team of chemists combines experience
in pharmaceutical R&D and process development, fine chemicals,
parallel synthesis and medicinal chemistry to deliver unique chemistry
solutions to a range of drug discovery challenges. Peakdale operates
in several distinct markets providing novel screening compounds,
GPCR-targeted libraries, catalogue intermediates, custom synthesis
and contract research chemistry. Further information about the Company
can be obtained at www.peakdale.co.uk.
|
